BLT.AX - Benitec Biopharma Limited

ASX - ASX Delayed Price. Currency in AUD
0.0260
0.0000 (0.00%)
At close: 1:28PM AEDT
Stock chart is not supported by your current browser
Previous Close0.0260
Open0.0270
Bid0.0240 x 0
Ask0.0240 x 0
Day's Range0.0250 - 0.0270
52 Week Range0.0220 - 0.1450
Volume460,929
Avg. Volume549,292
Market Cap8.353M
Beta (5Y Monthly)1.74
PE Ratio (TTM)N/A
EPS (TTM)-0.0360
Earnings DateJun 01, 2018 - Jun 02, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est3.00
  • PR Newswire

    Benitec Announces Supreme Court of Queensland Approval for Redomicile

    Benitec Biopharma Limited (Benitec or the "Company") (ASX: BLT; NASDAQ: BNTC; NASDAQ: BNTCW) today announce that the Supreme Court of Queensland ("Court") has approved the scheme of arrangement to redomicile the Benitec group from Australia to the United States of America.

  • PR Newswire

    Benitec Announces Results of Scheme Meeting

    Benitec Biopharma (ASX: BLT, NASDAQ: BNTC) ("Benitec" or the "Company"), a biotechnology company developing novel genetic medicines via the proprietary DNA-directed RNA interference (ddRNAi) platform combining RNA interference with gene therapy, today announced that in accordance with Australian Listing Rule 3.13.2 and section 251AA of the Corporations Act 2001 (Cth), the shareholder resolution to redomicile Benitec to the USA was passed.

  • Is Benitec Biopharma (ASX:BLT) In A Good Position To Deliver On Growth Plans?
    Simply Wall St.

    Is Benitec Biopharma (ASX:BLT) In A Good Position To Deliver On Growth Plans?

    Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

  • PR Newswire

    Appendix 4C: Quarterly Cash Flow Report

    Benitec Biopharma (ASX: BLT, NASDAQ: BNTC) ("Benitec" or the "Company"), a biotechnology company developing novel genetic medicines via the proprietary DNA-directed RNA interference (ddRNAi) platform combining RNA interference with gene therapy, today announced its Appendix 4C for the quarter ending 31 December 2019.

  • PR Newswire

    ASX/NASDAQ ANNOUNCEMENT: Re-domiciliation to the United States

    Benitec Biopharma Limited ("Benitec" or the "Company") (ASX:BLT; NASDAQ:BNTC; NASDAQ:BNTCW) is pleased to announce its intention to redomicile from Australia to the United States of America. To implement the re-domiciliation, Benitec has entered into a Scheme Implementation Agreement dated 27 November 2019 with Benitec Biopharma Inc. ("Holdco"), a new US company incorporated for the purpose of effecting the re-domiciliation, pursuant to the terms of which Holdco will acquire all of the ordinary shares in Benitec ("Benitec Shares") and the warrants of Benitec listed on the Nasdaq Capital Markets ("Benitec Warrants") by way of two separate schemes of arrangement, pursuant to which:

  • Some Benitec Biopharma (ASX:BLT) Shareholders Have Taken A Painful 93% Share Price Drop
    Simply Wall St.

    Some Benitec Biopharma (ASX:BLT) Shareholders Have Taken A Painful 93% Share Price Drop

    Some stocks are best avoided. We really hate to see fellow investors lose their hard-earned money. For example, we...

  • Reuters

    Public consultation launched on global tailings dam standards

    A Swiss environmental expert launched on Friday a six-week public consultation as he spearheads efforts to create new global standards next year following the Vale dam disaster in Brazil. The safety of dams used to store mining waste, known as tailings, gained prominence after the collapse of Vale's dam at Brumadinho, Brazil, in January that killed an estimated 300 people. The International Council on Mining and Metals (ICMM) said in March it was working on new standards with the U.N. Environment Programme (UNEP) and ethical investors' body the Principles for Responsible Investment (PRI).

  • PR Newswire

    Benitec Biopharma Limited Announces US$2.25 Million Registered Direct Offering

    NASDAQ:BNTCW) ("Benitec" or the "Company") announces it has entered into a securities purchase agreement ("SPA") with certain sophisticated and professional investors in the United States ("Investors") to issue 2,800,000 American Depositary Shares ("ADSs"), with each ADS representing 20 fully paid ordinary shares, at a purchase price of US$0.70 per ADS, in a registered direct offering. The Investors will also be issued warrants to purchase up to 412,863 ADSs in aggregate, at a purchase price per warrant equal to US$0.6999 per ADS to be issued on exercise of the warrant ("Pre-Funded Warrants"). The Pre-Funded Warrants may be exercised at any time from issue, in whole or in part, at an exercise price of US$0.0001 per ADS issued on exercise (subject to certain adjustments), provided that the beneficial ownership of the relevant Investor in the total number of ADSs on issue may not exceed 9.99%.

  • PR Newswire

    Benitec Biopharma to present at Ladenburg Thalmann 2019 Healthcare Conference

    MELBOURNE, Australia , Sept. 19, 2019 /PRNewswire/ -- Benitec Biopharma Ltd (ASX: BLT, NASDAQ: BNTC), a gene therapy-focused biotechnology company developing novel genetic medicines derived from the proprietary ...

  • PR Newswire

    Benitec Biopharma Provides Update on BB-301 Oculopharyngeal Muscular Dystrophy (OPMD) Program

    MELBOURNE, Australia , Sept. 16, 2019 /PRNewswire/ --   Benitec Biopharma (ASX: BLT, NASDAQ: BNTC), a gene therapy-focused biotechnology company developing novel genetic medicines derived from the proprietary ...

  • Does Market Volatility Impact Benitec Biopharma Limited's (ASX:BLT) Share Price?
    Simply Wall St.

    Does Market Volatility Impact Benitec Biopharma Limited's (ASX:BLT) Share Price?

    If you own shares in Benitec Biopharma Limited (ASX:BLT) then it's worth thinking about how it contributes to the...

  • PR Newswire

    ASX/NASDAQ ANNOUNCEMENT Appendix 4C: Quarterly Cash Flow Report

    MELBOURNE, Australia , July 31, 2019 /PRNewswire/ -- Benitec Biopharma (ASX: BLT, NADSAQ: BNTC) ("Benitec" or the "Company"), a clinical-stage biotechnology company developing novel ...

  • Could The Benitec Biopharma Limited (ASX:BLT) Ownership Structure Tell Us Something Useful?
    Simply Wall St.

    Could The Benitec Biopharma Limited (ASX:BLT) Ownership Structure Tell Us Something Useful?

    If you want to know who really controls Benitec Biopharma Limited (ASX:BLT), then you'll have to look at the makeup of...

  • PR Newswire

    Update on Oculopharyngeal Muscular Dystrophy Program

    SYDNEY , June 6, 2019 /PRNewswire/ -- Benitec Biopharma Limited ("Benitec" or the "Company") (ASX:BLT; NASDAQ: BNTC; NASDAQ: BNTCW) today announced the termination of the License and ...

  • Should Benitec Biopharma Limited (ASX:BLT) Be Your Next Stock Pick?
    Simply Wall St.

    Should Benitec Biopharma Limited (ASX:BLT) Be Your Next Stock Pick?

    Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! As an investor, I look for investments which does not compromise one fundamental factor for...